expert roundtables by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
The use of splenectomy has declined in recent years with the introduction of additional medications for the treatment of patients with immune throm......READ MORE
expert roundtables by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Bleeding is the most clinically important outcome in immune thrombocytopenia (ITP), and therefore the goal of therapy in patients with ITP is to tr......READ MORE
expert roundtables by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Immune thrombocytopenia (ITP) is often chronic and refractory to treatment. A chart review of patients with treatment-refractory chronic ITP who we......READ MORE
expert roundtables by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Corticosteroids currently remain the mainstay of initial management of immune thrombocytopenia (ITP) for patients unless there is a contraindicatio......READ MORE
expert roundtables by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
New therapies and treatment recommendations for chronic immune thrombocytopenia (ITP) have emerged in the last decade, including the thrombopoietin......READ MORE
Platelet count is initially measured to determine disease severity and to determine the need for treatment in all patients newly diagnosed with imm......READ MORE
